• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非手术意向的直肠癌全新辅助治疗的相关结局。

Outcomes associated with total neoadjuvant therapy with non-operative intent for rectal adenocarcinoma.

作者信息

Asare Ebenezer, Venner Emily, Batchelor Hanna, Sanders Jason, Kunk Paul, Hedrick Traci, Hoang Sook, Reilley Matthew, Le Tri, Friel Charles, Janowski Einsley-Marie

机构信息

Department of Radiation Oncology, University of Virginia, Charlottesville, VA, United States.

University of Virginia School of Medicine, Charlottesville, VA, United States.

出版信息

Front Oncol. 2024 Jul 29;14:1374360. doi: 10.3389/fonc.2024.1374360. eCollection 2024.

DOI:10.3389/fonc.2024.1374360
PMID:39156701
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11328831/
Abstract

PURPOSE/OBJECTIVES: To evaluate rates of clinical complete response (cCR), surgery-free survival, permanent ostomy-free survival, and factors associated with these outcomes in patients treated with total neoadjuvant therapy (TNT) with intent for non-operative management of rectal adenocarcinoma.

METHODS

A retrospective review was conducted of patients treated with TNT for stage II-IV rectal adenocarcinoma (n=45) at our institution between 2013 - 2022 with curative intent. All patients received radiation with concurrent capecitabine and additional chemotherapy, either prior to or following chemoradiation (CRT), with intent for non-operative management. Response rates were determined based on post-treatment MRI and endoscopy. Kaplan-Meier method was utilized to estimate the 1- and 2-year surgery- and permanent ostomy-free survivals. Cox regression was used to evaluate associations between surgery- and permanent ostomy-free survivals and various factors of interest, including patient and tumor characteristics and clinical response. Chi-squared analysis compared rates of cCR and surgery by sequence of TNT modality and cell count ratios.

RESULTS

Of the 45 patients treated with TNT, most patients had low-lying rectal tumors with a median distance of 4.1 cm from the anal verge (range, 0.0 - 12.0). Overall, 64.4% (n=29) achieved cCR after TNT. 13 patients (28.9%) underwent surgical resection following TNT, 12 of whom had incomplete response and one who elected to undergo surgery after reaching cCR. At median follow up of 32.0 months (range, 7.1 - 86.1), 22.2% (n=10) of patients had a permanent colostomy, with only 2 of these completed for tumor regrowth after cCR. At one and two years, respectively, surgery-free survival was 77.3% and 66.2%, and permanent ostomy-free survival was 90.9% and 78.2%. Rates of cCR were higher in patients who received CRT first compared to those who received chemotherapy first (72.2% vs. 33.3%, =0.029) and rates of surgery were also lower in patients who received CRT first compared to those who received chemotherapy first (19.4% vs. 66.7%, p=0.005). On Cox regression model, cCR on 6 month post-CRT endoscopy was associated with surgery-free survival (p=0.006) and permanent ostomy-free survival (=0.033). Clinical response at earlier follow up points did not predict surgery- nor permanent ostomy-free survival.

CONCLUSION

These results support evidence that TNT may be a non-surgical option for select patients with rectal adenocarcinoma who desire organ preservation. In this investigation at a single institution, the treatment response on 6-month post-CRT endoscopy was the best predictor of surgery- and permanent ostomy-free survival, which are outcomes that are important to patient quality of life. CRT followed by consolidation chemotherapy was associated with higher rates of cCR and lower rates of surgery compared to those treated with induction chemotherapy.

摘要

目的/目标:评估接受全新辅助治疗(TNT)以非手术方式治疗直肠腺癌患者的临床完全缓解(cCR)率、无手术生存、无永久性造口生存以及与这些结局相关的因素。

方法

对2013年至2022年期间在本机构接受TNT治疗的II-IV期直肠腺癌患者(n = 45)进行回顾性研究,目的是治愈。所有患者在同步放化疗(CRT)之前或之后接受放疗并同时使用卡培他滨及额外化疗,目的是进行非手术治疗。根据治疗后的MRI和内镜检查确定缓解率。采用Kaplan-Meier方法估计1年和2年的无手术生存及无永久性造口生存。使用Cox回归评估无手术生存及无永久性造口生存与各种感兴趣因素之间的关联,包括患者和肿瘤特征以及临床缓解情况。卡方分析比较了TNT治疗方式顺序和细胞计数比例的cCR率和手术率。

结果

在接受TNT治疗的45例患者中,大多数患者患有低位直肠肿瘤,距肛缘的中位距离为4.1厘米(范围0.0 - 12.0厘米)。总体而言,64.4%(n = 29)的患者在TNT治疗后达到cCR。13例患者(28.9%)在TNT治疗后接受了手术切除,其中12例缓解不完全,1例在达到cCR后选择接受手术。在中位随访32.0个月(范围7.1 - 86.1个月)时,22.2%(n = 10)的患者有永久性结肠造口,其中只有2例是由于cCR后肿瘤复发而完成造口。在1年和2年时,无手术生存率分别为77.3%和66.2%,无永久性造口生存率分别为90.9%和78.2%。与先接受化疗的患者相比,先接受CRT的患者cCR率更高(72.2%对33.3%,p = 0.029),且先接受CRT的患者手术率也低于先接受化疗的患者(19.4%对66.7%,p = 0.005)。在Cox回归模型中,CRT后6个月内镜检查时的cCR与无手术生存(p = 0.006)和无永久性造口生存(p = 0.033)相关。早期随访时的临床缓解情况并不能预测无手术生存或无永久性造口生存。

结论

这些结果支持以下证据,即TNT可能是某些希望保留器官的直肠腺癌患者的非手术选择。在本单机构研究中,CRT后6个月内镜检查的治疗反应是无手术生存和无永久性造口生存的最佳预测指标,而这些结局对患者生活质量很重要。与接受诱导化疗的患者相比,CRT后巩固化疗与更高的cCR率和更低的手术率相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2ca/11328831/67d5470fecf4/fonc-14-1374360-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2ca/11328831/e924ba526ac6/fonc-14-1374360-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2ca/11328831/73f53c9ea56f/fonc-14-1374360-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2ca/11328831/5fe389475162/fonc-14-1374360-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2ca/11328831/67d5470fecf4/fonc-14-1374360-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2ca/11328831/e924ba526ac6/fonc-14-1374360-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2ca/11328831/73f53c9ea56f/fonc-14-1374360-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2ca/11328831/5fe389475162/fonc-14-1374360-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2ca/11328831/67d5470fecf4/fonc-14-1374360-g004.jpg

相似文献

1
Outcomes associated with total neoadjuvant therapy with non-operative intent for rectal adenocarcinoma.非手术意向的直肠癌全新辅助治疗的相关结局。
Front Oncol. 2024 Jul 29;14:1374360. doi: 10.3389/fonc.2024.1374360. eCollection 2024.
2
[Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].巩固性新辅助治疗或全新辅助治疗后低位直肠癌的保直肠手术:初步报告
Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Mar 25;23(3):281-288. doi: 10.3760/cma.j.cn.441530-20200228-00096.
3
ALLIANCE A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer.联盟A022104/NRG-GI010:杰纳斯直肠癌试验:一项随机II/III期试验,旨在测试三联化疗与双联化疗在局部晚期直肠癌患者的临床完全缓解率和无病生存率方面的疗效。
medRxiv. 2024 Apr 27:2024.04.25.24306396. doi: 10.1101/2024.04.25.24306396.
4
Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical Trial.总新辅助治疗的直肠癌患者临床反应分级的器官保存和生存:OPRA 随机临床试验的二次分析。
JAMA Netw Open. 2024 Jan 2;7(1):e2350903. doi: 10.1001/jamanetworkopen.2023.50903.
5
[Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].[局部晚期高危直肠癌患者新辅助综合治疗的疗效与安全性分析]
Zhonghua Wei Chang Wai Ke Za Zhi. 2019 Apr 25;22(4):349-356. doi: 10.3760/cma.j.issn.1671-0274.2019.04.007.
6
Non-operative management after chemoradiotherapy plus consolidation or sandwich (induction with bevacizumab and consolidation) chemotherapy in patients with locally advanced rectal cancer: a multicentre, randomised phase II trial (NOMINATE trial).局部晚期直肠癌患者在放化疗后进行非手术治疗加巩固或夹心(贝伐珠单抗诱导和巩固)化疗:一项多中心、随机的 II 期试验(NOMINATE 试验)。
BMJ Open. 2022 Mar 18;12(3):e055140. doi: 10.1136/bmjopen-2021-055140.
7
[Outcome of watch and wait strategy or organ preservation for rectal cancer following neoadjuvant chemoradiotherapy: report of 35 cases from a single cancer center].[新辅助放化疗后直肠癌的观察等待策略或器官保留结果:来自单一癌症中心的35例报告]
Zhonghua Wei Chang Wai Ke Za Zhi. 2017 Apr 25;20(4):417-424.
8
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.直肠癌的器官保留:一项II期随机对照试验,评估接受放化疗加诱导或巩固化疗以及全直肠系膜切除术或非手术治疗的局部晚期直肠癌患者的3年无病生存率。
BMC Cancer. 2015 Oct 23;15:767. doi: 10.1186/s12885-015-1632-z.
9
Organ Preservation in Patients with Rectal Cancer Treated with Total Neoadjuvant Therapy.直肠癌患者接受全新辅助治疗后的器官保存。
Dis Colon Rectum. 2021 Dec 1;64(12):1463-1470. doi: 10.1097/DCR.0000000000002122.
10
[Total neoadjuvant therapy followed by watch and wait approach or organ preservation for MRI stratified low-risk rectal cancer: early result from a prospective, single arm trial].[新辅助综合治疗后观察等待或对MRI分层低风险直肠癌行器官保留:一项前瞻性单臂试验的早期结果]
Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Mar 25;23(3):258-265. doi: 10.3760/cma.j.cn.441530-20200222-00070.

本文引用的文献

1
Colorectal cancer statistics, 2023.2023 年结直肠癌统计数据。
CA Cancer J Clin. 2023 May-Jun;73(3):233-254. doi: 10.3322/caac.21772. Epub 2023 Mar 1.
2
Integrated Intensified Chemoradiation in the Setting of Total Neoadjuvant Therapy (TNT) in Patients with Locally Advanced Rectal Cancer: A Retrospective Single-Arm Study on Feasibility and Efficacy.局部晚期直肠癌患者新辅助全疗程治疗(TNT)背景下的综合强化放化疗:一项关于可行性和疗效的回顾性单臂研究
Cancers (Basel). 2023 Feb 1;15(3):921. doi: 10.3390/cancers15030921.
3
Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial.
短程放疗联合化疗和手术与长程放化疗和手术的局部区域失败比较:RAPIDO 试验的 5 年随访。
Ann Surg. 2023 Oct 1;278(4):e766-e772. doi: 10.1097/SLA.0000000000005799. Epub 2023 Jan 20.
4
Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors.新辅助帕博利珠单抗治疗局部微卫星高度不稳定/错配修复缺陷型实体瘤。
J Clin Oncol. 2023 Apr 20;41(12):2181-2190. doi: 10.1200/JCO.22.01351. Epub 2023 Jan 9.
5
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer.循环肿瘤 DNA 分析指导 II 期结肠癌辅助治疗。
N Engl J Med. 2022 Jun 16;386(24):2261-2272. doi: 10.1056/NEJMoa2200075. Epub 2022 Jun 4.
6
Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy.直肠癌患者接受全新辅助治疗后的器官保存。
J Clin Oncol. 2022 Aug 10;40(23):2546-2556. doi: 10.1200/JCO.22.00032. Epub 2022 Apr 28.
7
Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR).多中心、随机、III 期临床试验:短期放疗联合化疗与长程放化疗治疗局部进展期直肠癌(STELLAR)。
J Clin Oncol. 2022 May 20;40(15):1681-1692. doi: 10.1200/JCO.21.01667. Epub 2022 Mar 9.
8
International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer.国际共识推荐意见:直肠癌患者接受(放)化疗后器官保存的关键结局指标
Nat Rev Clin Oncol. 2021 Dec;18(12):805-816. doi: 10.1038/s41571-021-00538-5. Epub 2021 Aug 4.
9
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.局部晚期直肠癌患者的 FOLFIRINOX 新辅助化疗和术前放化疗(UNICANCER-PRODIGE 23):一项多中心、随机、开放标签、III 期临床试验。
Lancet Oncol. 2021 May;22(5):702-715. doi: 10.1016/S1470-2045(21)00079-6. Epub 2021 Apr 13.
10
Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study.国际观察等待数据库中新辅助放化疗后观察等待管理的临床完全缓解者的无复发生存条件:一项回顾性、国际、多中心登记研究。
Lancet Oncol. 2021 Jan;22(1):43-50. doi: 10.1016/S1470-2045(20)30557-X. Epub 2020 Dec 11.